SonoScape Medical (SZSE:300633) Shareholders Have Earned a 19% CAGR Over the Last Three Years
SonoScape Medical (SZSE:300633) Shareholders Have Earned a 19% CAGR Over the Last Three Years
SonoScape Medical Corp. (SZSE:300633) shareholders might be concerned after seeing the share price drop 17% in the last quarter. But that shouldn't obscure the pleasing returns achieved by shareholders over the last three years. After all, the share price is up a market-beating 67% in that time.
上个季度股价下跌17%后,SonoScape Medical Corp.(深圳证券交易所股票代码:300633)的股东可能会感到担忧。但这不应掩盖股东在过去三年中获得的丰厚回报。毕竟,当时股价上涨了67%,超过了市场。
So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress.
因此,让我们调查一下,看看公司的长期表现是否与基础业务的进展一致。
To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
引用巴菲特的话说:“船只将在世界各地航行,但Flat Earth Society将蓬勃发展。市场上的价格和价值之间将继续存在巨大差异...”考虑市场对公司的看法发生了怎样的变化的一种不完美但简单的方法是将每股收益(EPS)的变化与股价走势进行比较。
SonoScape Medical was able to grow its EPS at 86% per year over three years, sending the share price higher. The average annual share price increase of 19% is actually lower than the EPS growth. So one could reasonably conclude that the market has cooled on the stock.
SonoScape Medical得以在三年内将其每股收益增长到每年86%,这推动了股价的上涨。19%的年平均股价涨幅实际上低于每股收益的增长。因此,人们可以合理地得出结论,该股市场已经降温。
The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).
该公司的每股收益(随着时间的推移)如下图所示(点击查看确切数字)。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240312/0-9983b2314425148de1cf280d98780de8-0-09913397d966939cbc89820a2eb1130e.png/big)
It is of course excellent to see how SonoScape Medical has grown profits over the years, but the future is more important for shareholders. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.
看到SonoScape Medical多年来如何增加利润当然是件好事,但对于股东来说,未来更为重要。可能值得一看我们的免费报告,了解其财务状况如何随着时间的推移而变化。
A Different Perspective
不同的视角
We regret to report that SonoScape Medical shareholders are down 18% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 13%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. On the bright side, long term shareholders have made money, with a gain of 6% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. Before deciding if you like the current share price, check how SonoScape Medical scores on these 3 valuation metrics.
我们遗憾地报告说,SonoScape Medical的股东今年下跌了18%(甚至包括股息)。不幸的是,这比整个市场13%的跌幅还要严重。但是,可能只是股价受到了更广泛的市场紧张情绪的影响。如果有很好的机会,可能值得关注基本面。好的一面是,长期股东赚了钱,在过去的五年中,每年增长6%。如果基本面数据继续显示长期可持续增长,那么当前的抛售可能是一个值得考虑的机会。在决定是否喜欢当前股价之前,请查看SonoScape Medical在这三个估值指标上的得分情况。
But note: SonoScape Medical may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).
但请注意:SonoScape Medical可能不是最值得购买的股票。因此,来看看这份过去盈利增长(以及进一步增长预测)的有趣公司的免费清单。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。